Make money? Yes, Icahn
This article was originally published in Scrip
So we know that activist shareholder Carl Icahn, after waging two proxy battles and threatening another to change the leadership and strategy at Forest Laboratories, will trouser a cool $600 million plus profit if Actavis succeeds in its $25bn bid for the US specialty pharma company (scripintelligence.com 19 February 2014 & 18 February 2014). And he is not the only winner as any other shareholders who bought Forest stock mid November 2009, at the same time as Icahn Associates, will have realized a 209% return.